July 10th 2024
Read about a woman with well-differentiated atypical carcinoid who experienced a 21% regression in primary tumor size after 12 months on neoadjuvant capecitabine and temozolomide.
San Diego Lung Symposia
September 7, 2024 - September 8, 2024
Register Now!
Pathology Implications for CEACAM5 as a Therapeutic Target in Advanced NSCLC
View More
Medical Crossfire®: What Are Effective Strategies for Onco-Nurses to Improve Outcomes in Patients with Small Cell Lung Cancer?
View More
Virtual Show Me the Data™: How HER2, HER3, and TROP2 Targeted Strategies Will Impact Evolving Paradigms in NSCLC
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
22nd Annual Winter Lung Cancer Conference®
January 31, 2025 - February 2, 2025
Register Now!
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
TRIDENT-1 Trial for Repotrectinib Shows Encouraging Data in Subgroup of Patients with NSCLC
August 20th 2020Early interim data from the registrational phase 2 TRIDENT-1 study of repotrectinib was reported by Turning Point Therapeutics, as well as regulatory feedback from the FDA regarding the TRIDENT-1 trial design.
PLCOm2012 Model May Be More Effective in Screening African Americans for Lung Cancer
August 19th 2020These findings suggest that the current lung cancer screening guidelines undercount African Americans and should therefore be modified to avoid worsening the observed disparities between white and African American ever-smokers in lung cancer outcomes.
Afatinib, Osimertinib Sequence Shows Promise for EGFR-Positive NSLC
August 10th 2020The GioTag study demonstrated that sequential afatinib and osimertinib improved overall survival among patients from the US with epidermal growth factor receptor mutation-positive non-small cell lung cancer and a T790M resistance mutation.
Global Lung Cancer Burden Suggests Need for Tailored Measures
July 31st 2020Researchers suggested that based on their findings, increased efforts are needed to implement intervention strategies tailored to local settings to effectively decrease the global lung cancer burden and reduce health inequality.
FDA Grants Breakthrough Therapy Designation to Osimertinib for Early-Stage EGFR+ NSCLC
July 30th 2020The FDA granted breakthrough therapy designation to osimertinib for the adjuvant treatment of patients with early-stage epidermal growth factor receptor-mutated non-small cell lung cancer after complete tumor resection with curative intent.
Phase 2 CITYSCAPE Trial Shows Promise for Tiragolumab in NSCLC
July 4th 2020Patients with chemotherapy-naïve, locally advanced, or metastatic non-small cell lung cancer who were treated with tiragolumab plus an anti-PD-L1 agent showed better efficacy versus single-agent checkpoint inhibitor therapy alone.
Updated Phase 3 ALEX Trial Data Finds Alectinib Maintains Significant Benefit in ALK+ NSCLC
June 25th 2020The updated findings indicated that alectinib demonstrated a clinically meaningful improvement in overall survival compared with crizotinib in patients with ALK-positive non-small cell lung cancer.
Roy S. Herbst, MD, PhD, Discusses ADAURA Trial and Future of Lung Cancer Treatment
June 12th 2020Roy S. Herbst, MD, PhD, of the Yale Cancer Center discussed the future of lung cancer treatment to follow the phase III ADAURA trial regarding osimertinib as adjuvant therapy to treat NSCLC presented at the 2020 ASCO Virtual Scientific Program.
Study Shows Increased Use of Immune Checkpoint Inhibitors in Patients with Advanced NSCLC
June 12th 2020In this retrospective cohort study, the use of immune checkpoint inhibitors among patients with advanced NSCLC with negative, low, or untested PD-L1 expression was found to have increased over time.